Major breakthroughs were reported in lung cancer, breast cancer, and melanoma. AI emerged as a top topic with over 40 studies. More than 360 RWE studies were reported, some showing superiority. HEOR studies included 26 cost-effectiveness analyses, over 40 treatment pattern studies, 150+ registry studies, and 70+ adherence reports.

Read more

Big Pharma presented over 300 studies, with nearly 100 from Pfizer, BMS, and J&J. RWE led with 324 presentations, followed by CEA and QoL. AI emerged as a key topic with 30+ studies, showing potential for HEOR applications.

Read More

At ECCO 2022 there were 1,220 presentations on ulcerative colitis (UC) and Crohn’s disease (CD), with Real-World Evidence (RWE), quality of life (QoL), and endoscopic remission as top themes. Takeda, Janssen, and Pfizer's studies focused on RWE, randomized trials, and mucosal healing, respectively.

Read More